FVB/N-Tg(tetO-Kras2)12Hev/J

Stock number: 004375
Product name: K-Ras4b^G12D responder
Research areas: Cancer Research, Research Tools

Description

These K-Ras4b^G12D responder mice express a transgene containing activated rat Kras under the regulation of a tetracycline-responsive promoter element (TRE; tetO).

Detailed description

Mice that are homozygous for the transgene are viable and fertile. These transgenic mice express activated rat Kras (Kras4b^G12D) under the regulation of a tetracycline-responsive promoter element (TRE; tetO). When these mice are mated to strains containing transgenes encoding either rtTA (reverse tetracycline trans-activator protein) or tTA (the tetracycline trans-activator), activated Kras expression in the bitransgenic animals can be induced by administration or withdrawl, respectively, of the tetracycline analog, doxycycline. This strain represents an effective tool for generating tissue specific mutants that would be useful models for studying oncogene activation in human carcinogenesis.

Development

A transgenic construct containing the mutant gene (Kras4b^G12D) under the regulation of a tetracycline-responsive promoter element (TRE; tetO), the mp-1 intron and polyadenylation site sequence, and a minimal CMV promoter was injected into FVB/N blastocysts.

Allele

Symbol: Tg(tetO-Kras2)12Hev
Name: transgene insertion 12, Harold E Varmus
MGI accession ID: MGI:2179992
Generation method: Transgenic
Attributes: Inducible; Inserted expressed sequence
Marker symbol: Tg(tetO-Kras2)12Hev
Marker name: transgene insertion 12, Harold E Varmus
Chromosome: UN
Strain of origin: FVB/N
Expressed genes: Kras,KRAS proto-oncogene, GTPase,rat
Molecular note: The transgene expresses the mutant gene Kras4b^G12D, under the control of a tetracycline-responsive promoter element (tTA), mp-1 intron polyadenylation site sequence, and a minimal CMV promoter.
General note: Homozygous transgenic mice are viable and fertile. In conjunction with a second transgene encoding either rtTA (reverse tetracycline trans-activator protein) or tTA (the tetracycline trans-activator), mice carrying Tg(tetO-Kras2)12Hev show tissue-specific expression of the mutated K-ras transgene that may be induced or suppressed by administration of the tetracycline analog, doxycycline. Cessation or initiation of doxycycline treatment in bitransgenic strains containing, respectively, rtTA or tTA, will result in a rapid decrease of expression of the transgene.